Immunicon cuts staff 40%
This article was originally published in The Gray Sheet
Executive Summary
Cell and molecular-based human diagnostic and life sciences research firm reduces its workforce by 45 employees, or 40% of its full-time equivalent platform development, R&D and marketing staff. The reduction in force comes after the firm recently lost its bid to end a 20-year exclusive marketing agreement with Johnson & Johnson/Veridex for its CellSearch cancer test, and reflects the potential impact of the arbitration decision on Immunicon's commercialization efforts, the firm says (1"The Gray Sheet" March 10, 2008, In Brief). The company expects to take a related charge of $1.3 million-$1.5 million in the first fiscal quarter of 2008
You may also be interested in...
Veridex reigns in Immunicon
Diagnostics maker Immunicon lost its bid to end a 20-year exclusive marketing agreement with Johnson & Johnson/Veridex March 3, when the American Arbitration Association found that Veridex did not fault on its agreement to use its "best efforts" to market Immunicon's CellSearch circulating tumor cell assay, as Immunicon had alleged (1"The Gray Sheet" June 11, 2007, p. 10). Veridex also triumphed on its counterclaim that Immunicon was in "material breach" of the contract and was awarded $304,013. CellSearch is FDA-cleared to predict progression-free and overall survival in patients with metastatic breast, colorectal or prostate cancers
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.